Rolf Brekken
Professor
Surgery, Hamon Center for Therapeutic Oncology, Pharmacology
UT Southwestern Medical Center
United States of America
Biography
Dr. Rolf Brekken received his Bachelor of Arts degree from Luther College in Decorah, Iowa and his PhD from UT Southwestern Graduate School of Biomedical Sciences. His graduate research was focused in the use of Vascular Endothelial Growth Factor (VEGF) as a target for the therapy of solid tumors. He completed his postdoctoral training in the Department of Vascular Biology at the Hope Heart Institute in Seattle, Washington. His research interests include angiogenesis and extracellular matrix remodeling in tumors and the development and evaluation of novel therapies for cancer. The laboratory is particularly interested in the biology of therapy and how the tumor microenvironment effects therapeutic efficacy. Dr. Brekken is currently the Effie Marie Cain Research Scholar in Angiogenesis Research and is a principal investigator in the Hamon Center for Therapeutic Oncology Research.
Research Interest
Angiogenesis & ECM signaling Cancer Therapy Immune therapy Metastasis Tumor Microenvironment
Publications
-
Neutralizing murine TGFßR2 promotes a differentiated tumor cell phenotype and inhibits pancreatic cancer metastasis. Ostapoff KT, Kutluk Cenik B, Wang M, Ye R, Xu X, Nugent D, Hagopian MM, Topalovski M, Rivera LB, Carroll KD, Brekken RA Cancer Res. 2014 Jul
-
Warfarin blocks Gas6-mediated Axl activation required for pancreatic cancer epithelial plasticity and metastasis. Kirane A, Ludwig KF, Sorrelle N, Haaland G, Sandal T, Ranaweera R, Toombs JE, Wang M, Dineen SP, Micklem D, Dellinger MT, Lorens JB, Brekken RA Cancer Res. 2015 Jul
-
Fibulin-5 Blocks Microenvironmental ROS in Pancreatic Cancer. Wang M, Topalovski M, Toombs JE, Wright CM, Moore ZR, Boothman DA, Yanagisawa H, Wang H, Witkiewicz A, Castrillon DH, Brekken RA Cancer Res. 2015 Nov
